Skip to main content

Table 1 Baseline socio-demographic and clinical characteristics of patients included in this study (n = 1019)

From: Longitudinal changes in sports activity from pre-diagnosis to first five years post-diagnosis: a prospective Chinese breast cancer cohort study

Characteristics

Number of patients

Frequency, %

Age, mean ± SD, year

52.1 ± 8.8

 

Education level

 High school or below

868

85.2

 Collage or above

151

14.8

Marital status

 Married or cohabitating

728

71.4

 Unmarried or divorced or widowed

291

28.6

Household income (HKD/month)

  < 15,000

463

45.4

 15,000-30,000

326

32.0

 30,000-50,000

151

14.8

  ≥ 50,000

79

7.8

Employment status

 Full time

378

37.1

 Part time

129

12.7

 Not working

512

50.2

Menopausal status

 Pre-menopausal

539

52.9

 Post-menopausal

480

47.1

BMI at diagnosis, kg/m2

 Underweight (< 18.5)

37

3.6

 Normal (18.5–22.9)

488

47.9

 Overweight (23–24.9)

209

20.5

 Obese (≥25)

285

28.0

Number of comorbidities

 None

629

61.7

 1

259

25.4

 2

101

9.9

 ≥ 3

30

2.9

AJCC stage at diagnosis

 0-I

375

36.9

 II

471

46.2

 III

169

16.6

 Missing

4

0.4

Histology

 IDC

858

84.2

 ILC

31

3.0

 DCIS

56

5.5

 Others

74

7.3

ER status

 Positive

763

74.9

 Negative

233

22.9

 Missing

23

2.3

PR status

 Positive

598

58.7

 Negative

395

38.8

 Missing

26

2.6

HER 2 status

 Positive

274

26.9

 Negative

686

67.3

 Missing

59

5.8

Surgery

 Mastectomy

628

61.6

 Conservation

391

38.4

Chemotherapy

 Yes

774

76.0

 No

245

24.0

Radiotherapy

 Yes

721

70.8

 No

298

29.2

Endocrine therapy

 Yes

777

76.3

 No

242

23.7

Smoking status

 Yes

11

1.1

 No

1008

98.9

Drinking status

 Yes

15

1.5

 No

1004

98.5

  1. Abbreviations: SD standard deviation, HKD Hong Kong dollars, BMI body mass index, AJCC American joint Committee on cancer, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, DCIS ductal carcinoma in situ, ER estrogen receptor, PR progesterone receptor, HER 2 human epidermal-growth-factor receptor 2